These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 27859038)
1. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Treat L; Chapman KE; Colborn KL; Knupp KG Epilepsia; 2017 Jan; 58(1):123-127. PubMed ID: 27859038 [TBL] [Abstract][Full Text] [Related]
2. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Press CA; Knupp KG; Chapman KE Epilepsy Behav; 2015 Apr; 45():49-52. PubMed ID: 25845492 [TBL] [Abstract][Full Text] [Related]
3. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511 [TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of oral cannabis extracts in children with epilepsy. Knupp KG; Rice JD; Helmkamp LJ; Galinkin J; Sempio C; Jost K; Chapman KE Seizure; 2019 Nov; 72():23-27. PubMed ID: 31550641 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Porcari GS; Fu C; Doll ED; Carter EG; Carson RP Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Hausman-Kedem M; Menascu S; Kramer U Brain Dev; 2018 Aug; 40(7):544-551. PubMed ID: 29674131 [TBL] [Abstract][Full Text] [Related]
7. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Mitelpunkt A; Kramer U; Hausman Kedem M; Zilbershot Fink E; Orbach R; Chernuha V; Fattal-Valevski A; Deutsch L; Heffetz D; Sacks H Epilepsy Behav; 2019 Sep; 98(Pt A):233-237. PubMed ID: 31394352 [TBL] [Abstract][Full Text] [Related]
8. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Porter BE; Jacobson C Epilepsy Behav; 2013 Dec; 29(3):574-7. PubMed ID: 24237632 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. Wheless JW; Dlugos D; Miller I; Oh DA; Parikh N; Phillips S; Renfroe JB; Roberts CM; Saeed I; Sparagana SP; Yu J; Cilio MR; CNS Drugs; 2019 Jun; 33(6):593-604. PubMed ID: 31049885 [TBL] [Abstract][Full Text] [Related]
10. Cannabis for pediatric epilepsy: protocol for a living systematic review. Elliott J; DeJean D; Clifford T; Coyle D; Potter B; Skidmore B; Alexander C; Repetski AE; McCoy B; Wells GA Syst Rev; 2018 Jul; 7(1):95. PubMed ID: 30021618 [TBL] [Abstract][Full Text] [Related]
11. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Tzadok M; Uliel-Siboni S; Linder I; Kramer U; Epstein O; Menascu S; Nissenkorn A; Yosef OB; Hyman E; Granot D; Dor M; Lerman-Sagie T; Ben-Zeev B Seizure; 2016 Feb; 35():41-4. PubMed ID: 26800377 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cannabis for treating children with refractory epilepsy. Neale M Nurs Child Young People; 2017 Sep; 29(7):32-37. PubMed ID: 29115760 [TBL] [Abstract][Full Text] [Related]
13. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Thome-Souza S; Kadish NE; Ramgopal S; Sánchez Fernández I; Bergin AM; Bolton J; Harini C; Libenson M; Olson H; Peters J; Poduri A; Rotenberg A; Takeoka M; Kothare SV; Kapur K; Bourgeois BF; Loddenkemper T Epilepsia; 2014 Aug; 55(8):1235-44. PubMed ID: 25070475 [TBL] [Abstract][Full Text] [Related]
14. The case for medical marijuana in epilepsy. Maa E; Figi P Epilepsia; 2014 Jun; 55(6):783-6. PubMed ID: 24854149 [TBL] [Abstract][Full Text] [Related]
15. Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group. Epilepsia; 1991; 32(3):407-16. PubMed ID: 2044502 [TBL] [Abstract][Full Text] [Related]
16. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080 [TBL] [Abstract][Full Text] [Related]
17. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort. McGinnis E; Kessler SK Epilepsia; 2016 Sep; 57(9):1416-25. PubMed ID: 27430392 [TBL] [Abstract][Full Text] [Related]
18. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573 [TBL] [Abstract][Full Text] [Related]
19. Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia. Neubauer D; Perković Benedik M; Osredkar D Epilepsy Behav; 2018 Apr; 81():79-85. PubMed ID: 29526578 [TBL] [Abstract][Full Text] [Related]
20. Retrospective study of the use of levetiracetam in childhood seizure disorders. Koukkari MW; Guarino EJ J Child Neurol; 2004 Dec; 19(12):944-7. PubMed ID: 15704867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]